Nociception-specific blink reflex: pharmacology in healthy volunteers

JCA Marin1, AR Gantenbein1,4,5, K. Paemeleire1,6, H. Kaube1,7 and PJ Goadsby1,2,3*

Abstract

Background: The physiology and pharmacology of activation or perception of activation of pain-coding trigeminovascular afferents in humans is fundamental to understanding the biology of headache and developing new treatments.

Methods: The blink reflex was elicited using a concentric electrode and recorded in four separate sessions, at baseline and two minutes after administration of ramped doses of diazepam (final dose 0.07 mg/kg), fentanyl (final dose 1.11 μg/kg), ketamine (final dose 0.084 mg/kg) and 0.9 % saline solution. The AUC (area under the curve, μV*ms) and the latency (ms) of the ipsi- and contralateral R2 component of the blink reflex were calculated by PC-based offline analysis. Immediately after each block of blink reflex recordings certain psychometric parameters were assessed.

Results: There was an effect due to DRUG on the ipsilateral ($F_{3,60} = 7.3$, $P < 0.001$) AUC as well as on the contralateral ($F_{3,60} = 6.02$, $P < 0.001$) AUC across the study. A significant decrement in comparison to placebo was observed only for diazepam, affecting the ipsilateral AUC. The scores of alertness, calmness, contentedness, reaction time and precision were not affected by the DRUG across the sessions.

Conclusion: Previous studies suggest central, rather than peripheral changes in nociceptive trigeminal transmission in migraine. This study demonstrates a robust effect of benzodiazepine receptor modulation of the nociception specific blink reflex (nBR) without any μ-opiate or glutamate NMDA receptor component. The nociception specific blink reflex offers a reproducible, quantifiable method of assessment of trigeminal nociceptive system in humans that can be used to dissect pharmacology relevant to primary headache disorders.

Keywords: Migraine; Trigeminovascular system; Nociception specific blink reflex (nBR); Pharmacology

Background

The physiology and pharmacology of head pain underpins understanding of the various syndromes and development of new therapies for conditions such as migraine and cluster headache. Migraine is an episodic brain disorder that affects about 15–18 % of the population [1], is the most common cause of disability due to a neurological disorder [2] and has been estimated to be the most costly neurological disorder in the European Community at more than €27 billion per year [3]. Major therapeutic development, in the form of relatively specific and effective acute [4, 5] and preventive [6, 7] treatments of migraine have provided impetus to understand their mechanism of action. Since activation, or the perception of activation, of pain-coding trigeminovascular afferents underlies most disabling primary headaches [8], understanding human trigeminal mechanisms is essential for therapeutic development. The description of a method for activating the trigeminal system in humans to study pain-induced responses [9] has spurred many studies of this crucial pathway [10].

The blink reflex (BR) is a physiological, protective trigeminofacial reflex aimed at facilitating eyelid closure as a response to a threatening and potentially harmful stimulus [11]. In clinical practice the BR can be elicited when the skin innervated by the supraorbital nerve is electrically stimulated and a compound muscle action potential (CMAP) from the surface of the orbicularis

* Correspondence: peter.goadsby@kcl.ac.uk
1NIHR-Wellcome Trust King’s Clinical Research Facility, King’s College Hospital, London, UK
2Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, King’s College, London, UK
Full list of author information is available at the end of the article

© 2015 Marin et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
oculi muscle is recorded. The afferent portion of BR is supplied by branches of the trigeminal nerve, and the efferent volley is conducted by branches of the facial nerve. Suprasegmental influences on the BR are less well understood, but evidence from studies in patients with movement disorders, stroke and multiple sclerosis suggest input from the central cortex, basal ganglia and thalamus [12]. The reflex response consists of three components – R1, R2, and R3. R1 is mediated by exteroceptive A-beta fibers that project to low-threshold mechanoreceptive neurons in the pons [11, 13]. This response has an ipsilateral oligosynaptic reflex arc connecting the Gasserian ganglion to the pontine sensory nucleus of the trigeminal nerve and subsequently to the ipsilateral facial nucleus [14]. The R2 response is mediated by A-beta and A-delta fibers, projecting to wide dynamic range (WDR) neurons in the medulla including this of the spinal trigeminal nucleus [15]. R3 is mediated by A-beta and A-delta fibers and the precise connections are debated [16]. R3 and R2 are bilateral responses elicited by both noxious and innocuous stimuli. Only R2 can be elicited by selective activation of nociceptors [17]. Kaube and colleagues [9] developed a novel concentric electrode to allow specific study of nociceptive components of the R2 component of the reflex, the nociception-specific blink reflex (nBR).

It has been reported that fentanyl, an opioid receptor agonist, and diazepam both reduce the R2 component of the blink reflex [18]. Ketamine, despite its use in pain [19], has only infrequently been studied in migraine [9, 20], and most recently in migraine aura [21]. In this study we sought to explore the pharmacology of the nociceptive portion of the R2 response using the novel concentric electrode, and thus provide data in humans on some aspects of the pharmacology of this important synapse.

Methods

Demographics

The study was approved by The National Hospital for Neurology and Neurosurgery and The Institute of Neurology Joint Research Ethics Committee and Directorate for Research and Development. Male volunteers (n = 31) aged between 21 and 37 years underwent initial screening assessment, which included a careful history and physical examination, after signing an informed consent document that explained and described the study. Ten subjects were unsuitable because of intercurrent medical issues (n = 6) or for practical (n = 4) reasons, the latter being that they could not agree to attend on repeated occasions. Twenty-one non-smoking [22] subjects 27 ± 4 years old (mean ± SD) with unremarkable medical history, including no history of a headache disorder, normal physical examination and clinical laboratory tests, including negative urine drug screening, were recruited into the study. None of the volunteers received any prescribed medication for 30 days prior to the screening or after entering the study, for its entire duration. No medication was used during the 24 h prior to the recordings. Alcohol consumption was restricted to less than 10 units per week, with no intake for 24 h prior to and after each recording.

Recordings

All recordings were carried out between 9.00 and 17.30, with at least one common to all investigator blinded to the treatment (JCAM), under similar conditions and using the same verbal instructions on each occasion. The subjects were lying supine, in a comfortable adjustable bed in a warm room with dim light, keeping their eyes closed during the recordings. When required, gentle pressure was applied on the eye lids by an eye pad, helping the subjects to relax, in order to avoid interference by eyelid fluttering and thus reduce noise. EMG recordings were obtained from bilateral gold-plated surface electrodes placed infraorbitally over the belly of the orbicularis oculi muscle (different) and the lateral orbital ridge (indifferent); acquisition band width 1 to 1000 Hz (in isolated cases the lower cut off frequency was increased from 1 to 20 Hz to avoid clipping of the signal due to pronounced EOG responses), sampling rate 2.5 kHz (750 data points/sweep), sweep length 300 ms, amplifier gain 10,000 X (micro 1401, Signal Version 2, Cambridge Electronic Design, UK).

Stimulation

Blink reflexes were elicited with a custom built concentric electrode in using a printed circuit board design: central platinum cathode (D: 0.5 mm) and an external anode ring (D: 6 mm; thickness 1 mm), providing a stimulation area of 20 mm², placed about 10 mm above the right supraorbital foramen [9]. Stimulation was performed with a constant current source (Stimulator DS7A Digitimer, UK) by delivering a train of three square wave monopolar (positive) pulses [23], each lasting 0.5 ms, with an interpulse interval of 4 ms, maximum voltage 400 V. The current intensity for nociception-specific stimulation was 0.5–1.8 mA (mean 0.95 ± 0.19 mA), representing 2–4 times individual threshold for pin-prick perception (mean 0.31 ± 0.06 mA) [24]. Each session (of a total of four) consisted of four blocks (one at the base line and one after each dose, see below), separated by 10 min. Each block consisted of seven sweeps with an inter-stimulus interval of 12–18 s (randomized, uniform distribution). Grounding to earth was secured by a moist wrist band electrode or by a standard disposable ECG gel electrode placed over the mastoid protuberance.
Study design
In a single-center, randomized, double-blinded, placebo-controlled, crossover, four-arm study, the sensitivity of the blink reflex, as a marker of the central activity of diazepam, fentanyl and ketamine, was assessed versus specific CNS related parameters.

The volunteers were randomly assigned to receive a sequence of four treatments each, on four different occasions, separated by a washout period of a minimum four days.

Treatments
The subjects were cannulated and received either a ramped dose of intravenous diazepam: initial dose 0.03 mg/kg with two subsequent increments of 0.02 mg/kg each [25]; intravenous fentanyl: initial dose 0.37 μg/kg with two additional increments of 0.37 μg/kg each [26, 27]; intravenous ketamine: initial dose 0.028 mg/kg with two subsequent identical increments of 0.028 mg/kg [28–30], or intravenous placebo. Placebo was given as pure saline infusion and the active drugs were mixed with saline solution, all administered from a 50 ml volume syringe. Each infusion (dose increment), including placebo increments, was delivered over two minutes (300 ml/h) using an IVAC (TIVA ALARIS Medical Systems, Hampshire, UK) infusion pump.

Data collection
Continuous telemetric ECG, pulse, oxygen saturation and respiratory rate monitoring and intermittent (every 10 min) blood pressure measurements were performed during and two hours following the experiments (Philips C3 Patient Monitor 862474, USA). During every session, assessments of the blink reflex (see Statistical analysis) took place at the base line and two minutes after each dose increment, respectively.

Psychometric tests
Immediately after each block of blink reflex recordings certain psychometric parameters were objectively assessed by measuring the speed of reaction and the accuracy of responses to visual stimuli (as described below) and subjectively, using a computer adapted (Matlab 5.3, The MathWorks, Natick, MA, US) version of Bond Lader Rating Scale [31]. The test consisted of 16 pairs of opposite adjectives, each pair presented separately, with the opposite words delineating a 155 mm long and 20 mm wide bar, horizontally centred on a 15 in. Dell computer screen, positioned at a comfortable distance and in an appropriate visual angle. The subjects were instructed to mark the extent to which they felt the two opposite adjectives corresponded to their state of mind (i.e. closer to one quality and more distanced from its opposite) using a cross-hair cursor controlled by a mouse. The distance in mm was measured, the scores reversed and then analyses were made on three different fields, measuring alertness, calmness and contentedness.

To examine the three independent hypotheses regarding opioid, benzodiazepine and glutamatergic involvement in the nociception-specific blink reflex the ANOVA with repeated measures regard treatment episodes as related within subjects and examined the DRUG main effect with Bonferroni correction (SPSS for Windows). If Mauchly’s test of sphericity was violated, we made appropriate corrections to degrees of freedom according to Greenhouse–Geisser. Significance was assessed at the $P < 0.05$ level.

Results
All subjects completed the entire cross-over with no drop-outs. The volunteers had a mass of 72 ± 8 kg and were 1.8 ± 0.1 m in height.
Baseline data
Baseline blood pressure (mean arterial pressure, MAP = 2/3* Diastolic + 1/3 *Systolic) was 87 ± 2 mmHg, heart rate 62 ± 2 beats/min, respiratory rate was 20 ± 1 breaths per minute and oxygen saturation 98 ± 1 %.

Blink reflex
The baseline ipsilateral AUCs (μV.ms) for the four visits (ketamine, diazepam, fentanyl and placebo) were (mean ± SEM): 2082 ± 283, 1892 ± 299, 2340 ± 376 and 2011 ± 341, respectively. These were highly reproducible (alpha = 0.85, Fig. 1a). The baseline contralateral AUCs (μV.ms) for the four visits were: 1364 ± 239, 1156 ± 188, 1461 ± 324 and 1336 ± 306, respectively. The baseline contralateral latencies (ms) for the four visits were 47 ± 2, 47 ± 3, 46 ± 3 and 46 ± 3, respectively.

Neuropsychological tests
From the Bond-Lader scale the alertness (ketamine 30 ± 4, diazepam 23 ± 3, fentanyl 25 ± 3 and placebo 25 ± 4), calmness (28 ± 4, 24 ± 4, 27 ± 4 and 25 ± 3) and contentedness (25 ± 3, 21 ± 3, 21 ± 3 and 22 ± 3) scores were calculated. Reactions times (ms) for the four visits were: 479 ± 15, 447 ± 14, 406 ± 17 and 379 ± 18, respectively. Error rates for the four visits were: 13 ± 2, 15 ± 2, 17 ± 2 and 16 ± 2, respectively.

Overall analysis

Electrophysiology
The ipsilateral AUC demonstrated a reduction with time during the four measurement points in the overall analysis (F2.0,162.4 = 15.6, P < 0.001). There was a significant reduction in ipsilateral AUC attributable to the variable DRUG (F3,80 = 3.1, P = 0.03). For the contralateral AUC there was a reduction with time (F2.3,175.1 = 9.7, P < 0.001) without a significant DRUG effect for the overall analysis (F3,80 = 2.6, P = 0.057). There was no significant effect on the ipsilateral (F3,62 = 2.4, P = 0.064) or contralateral (F3,47 = 1.1, P = 0.36) latency attributable to DRUG. Latency data were not further analysed.

Neuropsychology
From the Bond-Lader scale for the alertness score (F3,80 = 1.02, P = 0.39), the calmness score (F3,80 = 0.79, P = 0.51), or the contentedness score (F3,80 = 0.36, P = 0.78), there was no effect of DRUG, although there was a subjective reduction in alertness over the measurement points (F1.8,141.3 = 48.1, P < 0.001) not seen with the calmness or contentedness scores. The reaction time was not affected across the measurement points (F3,240 = 0.19, P = 0.90) or by DRUG (F3,80 = 2.1, P = 0.10). The error rates were constant across time (F3,237 = 1.3 P = 0.28) and not altered by DRUG (F3,79 = 0.59, P = 0.62).

Treatment effects
There was a treatment effect across the study due to DRUG (F3.60 = 7.3, P < 0.001) in the ipsilateral AUC, that was further explored. Similarly there was a significant overall effect of DRUG on contralateral AUC (F3.60 = 6.02, P < 0.001).

Placebo
The ipsilateral AUC was constant for the placebo infusion at 2011 ± 341, 1907 ± 290, 2056 ± 333 and 1731 ± 258 (μV.ms), respectively, with alpha = 0.96. Similarly the contralateral AUC was constant at 1336 ± 306, 1305 ± 288, 1363 ± 309 and 1187 ± 307, respectively, and again with alpha = 0.96.
**Ketamine**
The AUCs were 2144 ± 288, 2445 ± 335, 2480 ± 328 and 1955 ± 256 (μV.ms), respectively. Ketamine had no effect on the ipsilateral AUC when compared with placebo (P = 0.84). Contralateral AUCs were 1377 ± 245, 1662 ± 304, 1630 ± 289 and 1410 ± 218, respectively. There was no significant effect of ketamine on contralateral AUC (P = 1.0).

**Fentanyl**
For fentanyl ipsilateral AUCs were 2340 ± 376, 2219 ± 294, 1852 ± 357 and 1673 ± 334 (μV.ms), respectively. There was no effect of fentanyl on ipsilateral AUC compared to placebo (P = 1.0). Contralateral AUCs were 1461 ± 324, 1515 ± 359, 1158 ± 295 and 849 ± 218, respectively. There was no significant effect of fentanyl on contralateral AUC (P = 1.0).

**Diazepam**
For diazepam ipsilateral AUCs were 1892 ± 299, 1301 ± 284, 756 ± 185 and 580 ± 120 (μV.ms), respectively. There was a significant decrement in ipsilateral AUC with diazepam compared to placebo (P = 0.047, Fig. 2). Contralateral AUCs were 1156 ± 188, 647 ± 161, 328 ± 83 and 284 ± 78. The effect of diazepam did not reach statistical significance for the contralateral AUC (P = 0.07).

**Discussion**
The study demonstrates an effect of benzodiazepine receptor modulation on the nociception-specific blink reflex without a detectable μ-opioid receptor or ketamine (glutamate-NMDA receptor) component in this model. The baseline effects were highly reproducible from session to session within subjects for four visits, consistent and extending previous observations [23], demonstrating the robustness of the method and thus its potential for serial assessments after suitable intervention.

A study by Kaube and colleagues using the novel concentric surface electrode [9] demonstrated an increase in the R2 component greater than 500 % on the headache side during acute migraine attacks [32]. An interictal deficiency in habituation of the nBR in migraine patients and also in asymptomatic individuals with a family history of migraine [33] emphasizes the potential for this reflex in understanding migraine pathophysiology.

**Nociception specific blink (nBR) reflex**
The nBR [9] R2 component is increased by more than 500 % in acute migraine [32]. This response seemed specific to migraine and was not observed in patients with acute frontal sinusitis [34], or in hypnic headache [35]. Interestingly, the nBR does not behave differently from controls in cluster headache in terms of habituation [36], although there is certainly lateralized facilitation [37].

The observation of an interictal persistent change raises the possibility of an endophenotypic marker for migraine [33]. This is important when one considers migraine as a substantially centrally mediated genetic disorder [8]. To this end triptans, serotonin 5-HT<sub>1B/1D</sub> receptor agonists [38], which are highly effective in migraine [39], have also been reported to affect the nBR. Aspirin and zolmitriptan suppressed the reflex by 68 and 78 %, respectively, in migraineurs during an acute attack [40]. Moreover, the A<sub>1</sub> receptor agonist GR79236 [41], which is effective in animal models of trigeminovascular nociception [42] and in acute migraine [43], also significantly inhibited the nBR. Taken together the data suggest that the model is helpful in understanding likely effects of various agents in migraine.

**nBR human pharmacology**
It has been reported that fentanyl, an opioid receptor agonist, and diazepam, which acts by potentiating the GABA mediated inhibitory effect, both reduce the R2 component of the blink reflex [18]. Dauthier and colleagues [44] found

![Fig. 2 The effect of the benzodiazepine receptor agonist diazepam on the nociception specific blink reflex, showing a significant (*, P < 0.05) reduction in the AUC (μV.ms) ipsilateral to stimulation (Panel a), and no significant effect contralaterally (b). Measurement periods t1 through t4 reflect the data collection epochs.](image-url)
that fentanyl 3 μg/kg did not alter the R2 response of the blink reflex. The dose used was slightly higher than the one employed here. Interestingly, fentanyl at a dose of 100 μg intramuscularly also failed to affect the R2 component of the blink reflex [45]. Taken with our studies the data suggest that opioid mechanisms are less important in the trigeminal system, although the latter studies were conducted with traditional electrodes with their limitations. In contrast, with the more conventional electrodes, it has been shown that zolmitriptan reverses blink reflex changes seen in migraine [46]. It is interesting that ketamine, despite its use in pain [19] did not alter the nBR. NMDA receptors, as a therapeutic target for migraine therapy have been discussed by Nicolodi and Sicutieri [20] who found that ketamine was effective as acute and preventive migraine treatment, when compared to placebo. Interestingly, when used in migraine with hemiplegic or prolonged aura, ketamine is useful for the aura component but not for the pain [21, 47].

**Trigeminocervical nociceptive pharmacology**

The new data are broadly consistent with those from lower species with some caveats [38]. Diazepam modulates the GABA<sub>A</sub> receptor, and it has been clearly shown in animals that GABA<sub>A</sub> mechanisms can modulate nociceptive trigeminovascular transmission at the second order synapse in the trigeminocervical complex [48]. Similarly, more direct evidence can be seen with studies of the benzodiazepine receptor in the anaesthetized cat with midazolam inhibiting transmission at a site where the effect is reversed by flumazenil [49]. Interestingly, in humans, the changes induced by diazepam on the R2 component of the blink reflex, were only partially reversed by flumazenil [18]. There is also a body of evidence from studies of neurogenically-mediated dorsal mechanisms for a role of GABA receptors in this system [50–52]. In contrast to the new data, animal studies do suggest the existence of the mu-opioid receptor in the trigeminocervical complex [53]. Similarly, there is certainly glutamatergic transmission at the trigeminocervical complex [54–56] and again effects in dural models [57, 58], suggesting a dose or more crucial difference in terms of human trigeminal nociceptive transmission.

It might be argued that diazepam’s influence on the R2 component of the blink reflex is due to a muscle relaxant effect. However, this was not observed in the current study with fentanyl. Moreover, previous work demonstrated a significant reduction of the R2 response with diazepam doses that did not alter the R1 response [44, 59]. Since R1 and R2 are mediated by the same muscle groups, a muscle relaxant effect as an explanation for the R2 response reduction seen after diazepam administration is not likely.

**Limitations**

The study has some important limitations that need consideration. When studying human volunteers it is imperative to consider safety. Such considerations limit the use of sedative treatments, particularly opioids whose major significant short term side effect is respiratory depression. Ketamine may have been under-dosed, although the results are consistent with other published data [47]. Krystal and colleagues [30] found that doses as low as 0.1 mg/kg caused psychiatric side effects in healthy volunteers when assessed by the Brief Psychiatric Rating Scale. Therefore, we chose a slightly lower dose (0.084 mg/kg), aiming, for both ethical and scientific purposes, to determine doses with minimal side effects, which is important since there are a paucity of human dose ranging studies of ketamine in this use. Ketamine is a short acting drug [29] with an effect we would expect to last no more than minutes and a small therapeutic window [26]. These pharmacokinetics favor a cumulative dose regimen as employed here [26], with test batteries performed immediately after or within 10 min after each dose increase. Our findings are also consistent with data showing that ketamine at a slightly lower dose than the total used here was effective as reducing the anxiety without altering the pain scores [28]. It is important to note the outcome of the study is limited to the pharmacology of the response elicited by the nBR, and cannot be generalized to the entire trigeminal system. Moreover, by using the nBR rather than a pain scale, we are limited in drawing inferences about how subjects may rate pain effects with these drugs.

**Conclusions**

We have shown in a carefully conducted three-way crossover study in volunteers a reduction of the nociception specific blink reflex with the benzodiazepine receptor agonist diazepam. We have seen no clear effect of fentanyl, the mu-opioid receptor agonist or ketamine, the non-competitive glutamate NMDA receptor blocker. The study showed a highly reproducible baseline from week to week within subjects. The nociception specific blink reflex offers a reproducible, quantifiable window with which to examine the trigeminal nociceptive system in humans. Studies of preventive medicines and putative new anti-migraine treatments may provide useful insights into both the pathophysiology of migraine and help accelerate medicine development.

**Authors’ contributions**

JCAM saw all the patients and conducted all the infusion studies, collected the data and revised the manuscript. AG designed the data collection system and revised the manuscript. KP designed the data collection system and revised the manuscript. HK designed the stimulation and data collection system, and revised the manuscript. PJG contributed clinical data, analytic review and wrote the manuscript. All authors read and approved the final manuscript.
Acknowledgements

The authors thank Paul Hammond for excellent technical assistance and Anna Stefanovic for assistance with some of these studies. Some parts of the King’s CRF are funded by the South London and the Maudsley Mental Health BRC. The views expressed are those of the authors and not necessarily those of the UK NHS, the NIHR or the Department of Health.

Competing interests

JCAM (h.marin@nhs.net): has received honoraria and consulting fees from electroCore LLC. 
AG (agantenbein@rehaclinic.ch): reports no conflicts of interest with the current work.

KP (koen.Paemeleire@uzgent.be): received honoraria as a speaker, advisor or investigator in clinical studies from Allergan, Almirall, Autonomic Technologies Inc, Coherex, Janssen-Cilag, Medtronic, Pfizer, Sandoz, and St Jude Medical.

HK (holger.kaupe@gmail.com): HK has consulted for Autonomic Technologies Inc and received honoraria for lectures from Allergan. 
PG is on the Advisory Board of eleurea, and has had grant support for experimental research. He is on Advisory Boards for Allergan, Colucid, MAP pharmaceuticals, Merck, Sharpe and Dohme, Autonomic Technologies Inc, Boston Scientific, Electrocore, Eli-Lilly, Medtronic, Linde gases, Arteaus, AlderBio and BristolMyerSquibb. He has consulted for Pfizer, Nevrocop, Lundbeck, Zogenix, Impax, Zosano and DrReddy, and has been compensated for expert legal testimony. He has grant support from Allergan, Amgen, MAP, and MSD. 
He has received honoraria for editorial work from Journal Watch Neurology and for developing educational materials and teaching for the American Headache Society.

Author details

1 NIHR-Wellcome Trust King’s Clinical Research Facility, King’s College Hospital, London, UK. 
2 Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, King’s College, London, UK. 
3Wellcome Foundation Building, King’s College Hospital, London SES 9PJ, UK. 
4Current address: Neurorehabilitation Center, RehaClinic, Bad Zurzach, Switzerland. 
5Current address: University of Zurich, Zürich, Switzerland. 
6Current address: Department of Neurology, Ghent University Hospital, Ghent, Belgium. 
7Neurology and Headache Center, Munich, Germany.

Received: 13 July 2015 Accepted: 2 September 2015

Published online: 08 October 2015

References

1. Lipton RB, Stewart WF, Diamond S, Diamond MI, Reed M (2001) Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 41:666–677.
2. Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, Shibuya K, Salomon JA, Abdalla S, Aboyans V, Abraham JM, Azzopardi A, Ahn SY, Ali MK, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Bahalim AN, Barker-Collo S, Barrero LH, Bartels CH, Basanez MG, Baxter A, Bell ML, Benjamin EJ, Bennett D, et al (2012) Years lived with disability (YLDs) for 160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380:2163–2196, PubMed
3. Andlin-Sobocki P, Jonsson B, Wittchen HU, Olesen J (2005) Cost of disorders of the brain in Europe. Eur J Neurol 12(Suppl 1):1–27
4. Goadsby PJ, Lipton RB, Ferrario MD (2002) Migraine: current understanding and treatment. N Engl J Med 346:257–270
5. Goadsby PJ (2013) Therapeutic prospects for migraine: can paradise be regained? Ann Neurol 74:423–434
6. Dodick DW, Goadsby PJ, Silberstein SD, Lipton RB, Olesen J, Ashina M, Wilks K, Kudrow D, Rohlmann C, Barharman B, Barrero LH, Butcher CH, Basanez MG, Baxter A, Bell ML, Benjamin EJ, Bennett D, et al (2012) Years lived with disability (YLDs) for 160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380(9859):2163–2196, PubMed
7. Dodick DW, Goadsby PJ, Spierings ELH, Scherer IC, Sweeney SP, Grayzel DS (2014) CGRP monoclonal antibody LY2951742 for the prevention of frequent episodic migraine. Lancet Neurol 13:1100–1107
8. Dodick DW, Goadsby PJ, Spierings ELH, Scherer IC, Sweeney SP, Grayzel DS (2014) CGRP monoclonal antibody LY2951742 for the prevention of frequent episodic migraine. Lancet Neurol 13:1100–1107
9. Akerman S, Holland P, Goadsby PJ (2011) Dienecephalic and brainstem mechanisms in migraine. Nat Rev Neurosci 12:570–584
10. Majis D, Ambrosini A, Bendtsen L, Ertes M, Kaupe H, Schoenen J (2007) Evaluation and proposal for optimization of neurophysiological tests in migraine: part 1—electrophysiological tests. Cephalalgia 27:1323–1338
11. Kudrow D, Kroll R, Kohrman B, Bargar R, Hirman J, Smith J (2014) CGRP monoclonal antibody LY2951742 for the prevention of frequent episodic migraine. Lancet Neurol 13:1100–1107
12. Esteban A (1999) A neurophysiological approach to brain stem reflexes. Blink reflex. Neurophysiol Clin 29:7–38
13. Misulis KE (1997) Essentials of clinical neurophysiology, 2nd edn. Boston, MA, Butterworth-Heinemann.
14. Trontelj MA, Trontelj J (1978) Reflex arc of the first component of the human blink reflex: a single motoneuron study. J Neurol Neurosurg Psychiatry 41:538–547
15. Ongerboer de Visser BW (1983) Anatomical and functional organization of reflexes involving the trigeminal system in man: jaw reflex, blink reflex, corneal reflex and ectroceptive suppression. Adv Neurol 39:727–738
16. Elrich J (2000) Brain stem reflexes: probing human trigeminal nociception. News Physiol Sci 15:94–97
17. Elrich J, Bromm B, Hopf HC (1997) Pain-evoked blink reflex. Muscle Nerve 20:265–270
18. Cuccu G, Ferracci S, Leardi MG, Fabbri A, Manfredi M (1991) Nociceptive quality of the orbicularis oculi reflexes as evaluated by distinct opiate- and benzodiazepine-induced changes in man. Brain Res 556:209–217
19. Zsigmond EK, Domino EF (1980) Ketamine: clinical pharmacology, pharmaco-kinetics and current clinical use. Anesth Rev 7:13–33
20. Nicodol M, Sicutieri F (1995) Exploration of NMDA receptors in migraine: therapeutic and theoretic implications. Int J Pharmacol Res 15:181–189
21. Målden S, Giffin NJ, Kaupe H, Goadsby PJ (2013) A randomized controlled trial of intranasal ketamine in migraine with prolonged aura. Neurology 80:64–67
22. Holle D, Heber A, Naegel S, Diener HC, Karsteschen 2014 Influences of smoking and caffeine consumption on trigeminal pain processing. J Headache Pain 15:39, PubMed PMCID: PMC4068369
23. Giffin NJ, Kaupe H, Zandieh A, Elrich J, Kaupe H (2004) The effect of multiple stimuli on the modulation of the ‘nociceptive’ blink reflex. Pain 108:124–128
24. Kaupe H, Elrich Z, Diener HC, Karsteschen 2002 Optimized stimulation and recording parameters of human ‘nociceptive specific’ blink reflex recordings. Clin Neurophysiol 113:1922–1936
25. Hommer DW, Matsuo V, Wolkowitz O, Chougos G, Greenblatt DJ, Waingarter H, Paul SM (1988) Benzodiazepine sensitivity in normal human subjects. Arch Gen Psychiatry 45:542–551
26. Tucker AP, Kim Y, Nadelson R, Goodchild CS (2005) Investigation of the potential effects on fentanyl by ketamine in humans: a double-blinded, randomised, placebo controlled, crossover study of experimental pain. BMC Anesthesiol 5:2
27. Peng P, Sandler A (1999) A review of the use of fentanyl analgesia in the management of acute pain in adults. Anesthesia 2005:69–599
28. Oda A, Iida H, Dohi S (2000) Patient anxiety stress after low-dose ketamine or fentanyl for epidural catheter placement. Can J Anaesth 47:910–913
29. Clements JA, Nimmo WS, Grant IS (1982) Bioavailability, pharmacokinetics, and analgesic activity of ketamine in humans. J Pharm Sci 71:539–542
30. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Douglas Bremner J, Waingartner H, Paul SM (1988) Benzodiazepine sensitivity in normal human subjects. Arch Gen Psychiatry 45:542–551
31. Bond A, Lader M (1974) The use of analogue scales in rating subjective feelings. Br J Med Psychol 47:211–270
32. Esteban A (1999) A neurophysiological approach to brain stem reflexes. Blink reflex. Neurophysiol Clin 29:7–38
33. Di Clemente L, Coppola G, Magis D, Fumal A, Zappulla S, Spergari R, Deppe J, Elrich J, Diener HC (2002) Acute migraine headache: possible sensitization of neurons in the spinal trigeminal nucleus? Neurology 58:1234–1238
34. Di Clemente L, Coppola G, Magis D, Fumal A, De Pasqua V, Di Piero V, Schoenen J (2007) Interictal habituation deficit of the nociceptive blink reflex: an endophenotypic marker for presymptomatic migraine? Brain 130:765–770

Marin et al. The Journal of Headache and Pain (2015) 16:87
52. Cutrer FM, Moskowitz MA (1996) The actions of valproate and neurosteroids in a model of trigeminal pain. Headache 36(10):579–585

53. Storer RJ, Akerman S, Goadsby PJ (2003) Characterization of opioid receptors that modulate nociceptive neurotransmission in the trigeminocervical complex. Br J Pharmacol 138:317–324

54. Storer RJ, Goadsby PJ (1999) Trigeminovascular nociceptive transmission involves N-methyl-D-aspartate and non-N-methyl-D-aspartate glutamate receptors. Neuroscience 90:137–1376

55. Classey JD, Knight YE, Goadsby PJ (2001) The NMDA receptor antagonist MK-801 reduces capsaicin-induced c-fos expression within rat trigeminal nucleus caudalis. Pain 76(3):29–48

56. Storer RJ, Cutrer FM (2000) Glutamatergic transmission in the trigeminal nucleus assessed with local blood flow. Brain Res 875:109–114

57. Mritoskostas DD, Sanchez del Rio M, Wauber C, Moskowitz MA, Cutrer FM (1998) The NMDA receptor antagonist MK-801 reduces capsaicin-induced c-fos expression within rat trigeminal nucleus caudalis. Pain 76(3):29–48

58. Mritoskostas DD, Sanchez del Rio M, Wauber C, Huang Z, Cutrer FM, Moskowitz MA (1999) Non-NMDA glutamate receptors modulate capsaicin-induced c-fos expression within trigeminal nucleus caudalis. Br J Pharmacol 127:623–630

59. Kimura J (1973) The blink reflex as a test for brain stem and higher central nervous function. In: Desmet JE (ed) New developments in electromyography and clinical neurophysiology. 3. Karger, Basel, pp 682–691